Dashboard
Manage Tickers

ARDXARDELYX, INC.

Nasdaq ardelyx.com


$ 6.37 $ 0.25 (4.08 %)    

Wednesday, 21-Aug-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 6.37
$ 6.36 x 1,200
-- x --
-- - --
$ 3.16 - $ 10.13
3,624,268
na
1.49B
$ 0.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 10-31-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 03-02-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-08-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-06-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-06-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-14-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 02-17-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-04-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-05-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-ardelyx-raises-price-target-to-11
HC Wainwright & Co. Maintains Buy on Ardel...
08/05/2024 17:47:34

HC Wainwright & Co. analyst Ed Arce maintains Ardelyx (NASDAQ:ARDX) with a Buy and raises the price target from $10 to $11.

citigroup-maintains-buy-on-ardelyx-raises-price-target-to-12
Citigroup Maintains Buy on Ardelyx, Raises...
08/02/2024 16:13:30

Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and raises the price target from $10 to $12.

what-6-analyst-ratings-have-to-say-about-ardelyx
What 6 Analyst Ratings Have To Say About A...
08/02/2024 15:01:29

wedbush-reiterates-outperform-on-ardelyx-maintains-11-price-target
Wedbush Reiterates Outperform on Ardelyx, ...
08/02/2024 13:06:47

Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $11 price target.

ardelyx-q2-2024-gaap-eps-007-beats-010-estimate-sales-73222m-beat-55019m-estimate
Ardelyx Q2 2024 GAAP EPS $(0.07) Beats $(0...
08/01/2024 20:23:54

Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30...

ardelyx-announces-publication-of-two-plain-language-summaries-from-xphozah-clinical-trials-in-current-medical-research-and-opinion
Ardelyx Announces Publication Of Two Plain...
07/31/2024 12:27:31

Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovati...

hc-wainwright--co-reiterates-buy-on-ardelyx-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Arde...
07/18/2024 19:02:58

HC Wainwright & Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:ARDX) with a Buy and maintains $10 price target.

ardelyx-files-lawsuit-over-medicare-drug-payment-rules-claims-it-will-limit-patient-access-to-kidney-disease-treatment
Ardelyx Files Lawsuit Over Medicare Drug P...
07/18/2024 18:50:58

Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug...

wedbush-reiterates-outperform-on-ardelyx-maintains-11-price-target
Wedbush Reiterates Outperform on Ardelyx, ...
07/18/2024 13:43:02

Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $11 price target.

citigroup-maintains-buy-on-ardelyx-lowers-price-target-to-10
Citigroup Maintains Buy on Ardelyx, Lowers...
07/03/2024 18:05:19

Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $14 to $10.

why-ardelyx-stock-is-dropping
Why Ardelyx Stock Is Dropping
07/02/2024 15:26:22

Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Cente...

to-preserve-patient-access-to-xphozah-tenapanor-ardelyx-has-chosen-not-to-apply-to-include-xphozah-in-centers-for-medicare--medicaid-services-end-stage-renal-disease-prospective-payment-system-transitional-drug-add-on-payment-adjustment
To Preserve Patient Access To Xphozah (Ten...
07/02/2024 11:04:21

Ardelyx's analysis of the CMS policy to include oral-only medicines in the PPS and the Calendar Year 2025 ESRD PPS Proposed...

ardelyx-presents-additional-data-detailing-educational-needs-for-ibs-c-management-across-healthcare-disciplines-at-2024-aanp-annual-conference
Ardelyx Presents Additional Data Detailing...
06/28/2024 12:19:52

analyst-expectations-for-ardelyxs-future
Analyst Expectations For Ardelyx's Future
06/20/2024 18:00:45

cantor-fitzgerald-reiterates-overweight-on-ardelyx
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:24:05

Cantor Fitzgerald analyst Louise Chen reiterates Ardelyx (NASDAQ:ARDX) with a Overweight.

how-is-the-market-feeling-about-ardelyx
How Is The Market Feeling About Ardelyx?
06/04/2024 19:00:14

piper-sandler-maintains-overweight-on-ardelyx-maintains-15-price-target
Piper Sandler Maintains Overweight on Arde...
05/24/2024 16:28:13

Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and maintains $15 price target.

watching-ardelyx-shares-hearing-traders-circulate-piper-note-saying-departure-of-coo-is-not-a-positive
Watching Ardelyx Shares; Hearing Traders C...
05/24/2024 16:03:24

what-analysts-are-saying-about-ardelyx-stock
What Analysts Are Saying About Ardelyx Stock
05/24/2024 15:00:33

wedbush-reiterates-outperform-on-ardelyx-maintains-15-price-target
Wedbush Reiterates Outperform on Ardelyx, ...
05/24/2024 14:08:33

Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $15 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION